UGT1A1 GENE POLYMORPHISM AND FREQUENCY OF HYPERBILIRUBINEMIA IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED BY NILOTINIB

Background. Polymorphisms in the UGT1А1 gene (especially the homozygous (TA)7/(TA)7genotype), which encodes the uridine diphosphate glucuronyltransferase 1 (UDP-GT) enzyme in hepatocytes, may manifest with isolated indirect hyperbilirubinemia. Hyperbilirubinemia is also most common laboratory abnormality in chronic myeloid leukemia (CML) patients treated by nilotinib.
Aim. To estimate the correlation between of UGT1А1 gene polymorphism and frequency of hyperbilirubinemia in CML patients treated by nilotinib.
Materials and methods. Our study included 100 CML patients treated by nilotinib. We analyzed their blood biochemistry, namely the level of bilirubin, the activity of liver enzymes (AST and ALT), the time to development of hyperbilirubinemia, and the time until normalization of blood biochemistry. We also studied the promoter region of the UGT1А1 gene in these patients with allele-specific polymerase chain reaction (AS-PCR).
Results. Indirect hyperbilirubinemia was observed in 84 (84%) of 100 patients. Of those, 41 (49%) had grade 1 hyperbilirubinemia, 33 (39%) had grade 2 hyperbilirubinemia, and 10 (12%) had grade 3 hyperbilirubinemia. Normal genotype (ТА)6/(ТА)6 was found in 71 (71%) patients, 19 (19%) patients had a heterozygous (ТА)6/(ТА)7 genotype, and 10 (10%) patients had a homozygous (ТА)7/(ТА)7 genotype. Eight of the 84 CML patients with hyperbilirubinemia (9,5%) had a transient elevation of ALT and AST: grade 1 in 1 case, grade 2 in 5 cases, and grade 3–4 in 2 cases.
Conclusion. In CML patients treated with nilotinib, grade 3 hyperbilirubinemia may be a sign of (ТА)7/(ТА)7 polymorphism in promoter region of the UGT1А1 gene. Low-grade hyperbilirubinemia occurs both in patients with normal UGT1А1 genotype and in patients heterozygous for the (ТА)7 polymorphism. No connection between UGT1А1 polymorphisms and elevated liver enzymes (ALT, AST) was established.

1. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540—3546.

2. Гусарова Г. А., Туркина А. Г., Домрачева Е. В. и др. Опыт ГНЦ РАМН по применению нилотиниба(Тасигна) у больных в хронической фазе хронического миелолейкоза при неудаче терапии иматинибом. Совре-менная онкология2010; 1:38—42.

3. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251—2259.

4. Гусарова Г. А., Туркина А. Г., Колошейнова Т. И. и др. Клинические аспекты применения нилотиниба при лечении больных с хроническим миелолейкозом в хронической фазе. Гематология и трансфузиология 2013; 57:3—11.

5. Bykova AV, Gusarova GA, Chelysheva EYu, Turkina AG. Long-term results and adverse events of second line Nilotinib therapy after Imatinib failure in patients with chronic myeloid leukemia in chronic phase in clinical practice. Blood 2013; 122:5181.

6. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995; 333:11715.

7. Monaghan G, Ryan M, Seddon R et al. Genetic variation in bilirubin UDP-glucuronosyltranferase gene promotor and Gilbert’s syndrome. Lancet 1996; 347:578—581.

8. Sugatani J, Yamakawa K, Yoshinari K et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292:492—497.

9. Рамазанов В. О., Габитова Д. М. Синдром Жильбера. Успехи совре-менного естествознания2011; 11:99.

10. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? PNAS 1998; 95:8170—8174.

11. Premawardhena A, Fisher CA, Liu YT et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 2003; 31:98—101.

12. Куропаткина Ю. В., Карабанов А. В., Шулятьев И. С. и др. Инсер-ция в промоторной области генаUGT1 и непереносимость лекарст-венных препаратов. Медицинская генетика2005; 4:216а—216.

13. Polyakov A, Kuropatkina J, Karabanov A et al. The correlation between insertion in the promoter region of the UGT1 gene and the tolerance of some xenobiotics. Eur J Hum Genet 2005; 13:273.

14. Singer JB, Shou Y, Giles F et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007; 21:2311—2315.

15. Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Доступно в интернете по адресу: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (по состоянию на4 апреля2017 г.).

16. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. PNAS 1977; 74:5463—5467.

17. Steegmann JL, Cervantes F, le Coutre P et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012; 53:2351—2361.